Overview

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Status:
Recruiting
Trial end date:
2023-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 study is to determine whether iptacopan is efficacious and safe for the treatment of PNH patients who are naive to complement inhibitor therapy
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals